Which Post-Market Device Documents Need Certified EU Translation

1 day ago

9 min read

Reviewers checking digital eIFU and post-market device translation assets

Six post-market document types decide whether a CE-marked device stays compliant after launch, and the ones that reach patients and users have to be in the national language of each market. Under the Medical Device Regulation, Regulation (EU) 2017/745, the language obligation in Article 10(11) and Annex I Section 23.1(d) does not stop at the first Instructions for Use. It follows every safety communication, every summary, and every label update for the life of the device.

AD VERBUM is an EU-hosted translation company that handles post-market medical device documentation, pairing a client-tuned LLM with certified device linguists under ISO 13485, ISO 17100, and ISO 27001. We keep post-market content consistent across every member-state language, from the first Field Safety Notice to the annual safety report.

Post-market surveillance is where most language gaps surface, because the volume is higher than at launch and the deadlines are shorter. Below are the six document types a manufacturer most often has to translate after a device is on the market, each with the MDR article that governs it and the language rule that applies. We have marked which ones need a national language and which stay in a single working language, because getting that split wrong wastes budget or misses a legal requirement.

What post-market surveillance covers

Every manufacturer runs a post-market surveillance system under Articles 83 and 84 of the MDR, built on a post-market surveillance plan set out in Annex III. The plan gathers field data, complaints, and clinical evidence, then feeds a set of reports and safety communications. Some of those documents go to a notified body or a competent authority. Others go to clinicians, patients, and distributors, and those are the ones the national-language rule catches.

The distinction matters for translation planning. A report read only by a regulator can often stay in one agreed working language. A notice read by a user in Lisbon, Helsinki, or Warsaw has to be in Portuguese, Finnish, or Polish. Treating both the same way is how manufacturers either overspend on translation they did not need or ship a safety message a user cannot read.

The post-market documents that need certified EU translation

These six document types account for most post-market translation demand. The first three reach patients and users, so they carry a hard national-language requirement. The last three are report-level documents where the language depends on who reads them.

1. Field Safety Notices

A Field Safety Notice is the message a manufacturer sends to users and patients when it takes a Field Safety Corrective Action, such as a recall, a software fix, or a use restriction. Article 89 of the MDR requires the notice to be written in an official Union language, or languages, determined by the member state where the corrective action is taken. Article 89 also requires that the content stays consistent across all member states, unless a national situation justifies a difference.

That combination is the hard part. The same facts, the same risk description, and the same instructions have to hold in every language at once, often on a short clock. A loose translation that softens a warning in one language and not another breaks the consistency the article demands. This is the document type where terminology control and certified review matter most, and where our work on MDR documents that need EU-language translation starts.

2. Summary of Safety and Clinical Performance

For implantable and Class III devices, Article 32 requires a Summary of Safety and Clinical Performance, the SSCP. It has two versions, one for healthcare professionals and one for patients, and the patient version has to be written in plain, non-technical language. Both are uploaded to EUDAMED and made available in the languages of the member states where the device is sold, so the SSCP is a recurring, multi-language translation job that updates as new clinical data arrives. Our detailed treatment of SSCP translation under Article 32 covers the two-audience split in full.

The patient version is the one that trips teams up. A translator who renders it accurately but keeps clinical register has still failed the readability requirement. Certified device linguists write the patient SSCP to be understood by a lay reader while keeping every claim faithful to the professional version.

Compliance team handing off medical device translation files

3. Updated Instructions for Use and labelling

Instructions for Use and labels are not a launch-only task. Every design change, new warning, or contraindication found through post-market surveillance triggers an IFU or label revision, and Article 10(11) with Annex I Section 23.1(d) keeps the national-language obligation on each revision. When a device moves to an electronic IFU under Regulation (EU) 2021/2226, the same national languages still apply, and the implant card under Article 18 carries its own member-state language rule.

The risk here is version drift. A warning added in the English master has to reach all 24 language versions, with the same wording and the same effective date. Terminology that stays fixed across every update is what keeps a label set audit-ready.

4. Periodic Safety Update Reports

The Periodic Safety Update Report, or PSUR, is required for Class IIa, IIb, and III devices under Article 86. It summarises post-market data, the benefit-risk conclusion, and any corrective action taken. Class IIb and Class III manufacturers update it at least annually, and for Class III and implantable devices it goes to the notified body through the electronic system.

The PSUR itself is usually accepted in a single working language agreed with the notified body, so it does not always need full national-language translation. It still needs precise regulatory language, and its inputs, including complaints and incident data pulled from multiple markets, often arrive in several languages that have to be rendered accurately before the analysis holds. The MDCG 2022-21 guidance sets out the expected PSUR structure.

5. Post-Market Surveillance Reports

For Class I devices, Article 85 requires a Post-Market Surveillance Report instead of a PSUR. It carries the same summary-and-conclusion purpose at a lower reporting burden, and it is kept up to date rather than filed on a fixed cycle. Like the PSUR, it is a report-level document that usually stays in one working language for the manufacturer and its authority.

Translation enters through the data feeding it. A Class I manufacturer selling across the EU collects complaints and user feedback in many languages, and those have to be understood correctly before they can be summarised. Machine output that misreads a complaint can distort the conclusion of the whole report.

6. Vigilance and trend reports

Serious incident reports under Article 87 and trend reports under Article 88 are the time-critical end of post-market work. Serious incidents carry reporting deadlines as short as 2 days for a serious public-health threat, 10 days for a death or serious deterioration, and 15 days for other serious incidents. These reports go to competent authorities, and the receiving authority can require its national language, which is why keeping device data consistent across languages, as covered in our note on EUDAMED device data before November 2026, matters before an incident happens, not during one.

Under deadline pressure there is no time to build terminology from scratch. A manufacturer that has already agreed device terms in every required language can render an incident report in hours. One that has not is negotiating vocabulary while the clock runs.

Hospital team reviewing device safety information and compliance controls

Which need a national language and which do not

The practical rule sorts post-market documents by who reads them, not by how important they are.

National language required, because a patient, user, or clinician reads it: Field Safety Notices (Article 89), the patient and professional SSCP (Article 32), and updated Instructions for Use and labelling (Article 10(11), Annex I 23.1(d)).
Usually one working language, because a notified body or competent authority reads it: the PSUR (Article 86), the Post-Market Surveillance Report (Article 85), and the PMCF evaluation report under Annex XIV Part B.
Language on request: vigilance and trend reports (Articles 87 and 88), where the competent authority receiving the report can require its own national language.

The report-level documents still depend on multilingual inputs, so translation quality affects them even when the final file stays in one language. The split tells you where a certified national-language translation is a legal requirement, and where accurate handling of source data is what protects the conclusion.

Where it goes wrong

The most common failure is treating a post-market safety document like marketing copy and running it through raw machine translation. A softened warning, a mistranslated dosage, or a dropped contraindication in one language version is a compliance defect, and machine-translation errors can delay a CE marking or force a re-issue. Segment-level engines also lose the cross-document consistency that Article 89 requires, because they translate each notice in isolation.

The second failure is fragmented terminology. When Field Safety Notices, SSCPs, and IFUs for the same device are translated by different suppliers at different times, the device name, the warning wording, and the clinical terms drift apart. An auditor comparing the label, the SSCP, and the latest safety notice then finds three versions of the same term. One managed term base across every post-market document is the fix.

Where AD VERBUM fits

We at AD VERBUM run post-market device translation on an ISO 13485 device quality management system paired with ISO 17100 certified review, so every notice, summary, and label update passes through a qualified device linguist and an independent reviewer. Our ISO 13485 translation workflow treats the whole post-market set as one program rather than a stream of separate jobs, which is what keeps terminology consistent across document types and languages.

Post-market content is often sensitive, so our processing runs on EU-hosted infrastructure we own, under ISO 27001, with no public-cloud transit and no training on your data. Secure enterprise translation is the default, terminology governance holds the device vocabulary fixed across every update, and our overview of which MDR documents need translation maps the full set for a device team.

Our medical device translation services

Our translation services for regulated sectors run on ISO 27001 and ISO 42001 certified, EU-hosted infrastructure, with no reliance on public cloud tooling for core processing. Every project runs through our AI+HUMAN hybrid workflow: we ingest client Translation Memories and Term Bases first, our proprietary LLM-based LangOps System generates output constrained by client terminology on client-tuned open-weight models, and our certified subject-matter experts review for technical accuracy and regulatory compliance. Our QA is aligned to ISO 17100 and ISO 18587, with sector-specific requirements such as ISO 13485 device quality management and MDR Article 10(11) language obligations applied where relevant. We serve Life Sciences, Legal, Finance, Defense, and Manufacturing clients across 150+ languages with 3,500+ subject-matter linguists. For teams managing audit-sensitive content, contact us to discuss your security and compliance requirements directly.

FAQ

Which post-market device documents must be translated into national languages?

Field Safety Notices under MDR Article 89, both versions of the Summary of Safety and Clinical Performance under Article 32, and updated Instructions for Use and labelling under Article 10(11) and Annex I 23.1(d). Each reaches a patient, user, or clinician, so the national-language rule applies. AD VERBUM produces these under ISO 13485 and ISO 17100.

Do PSURs and Post-Market Surveillance Reports need certified translation?

Usually not in full, because the PSUR under Article 86 and the PMSR under Article 85 go to a notified body or competent authority that accepts one agreed working language. Their inputs, such as complaints and incident data from several markets, still need accurate translation before the analysis is sound. AD VERBUM handles those multilingual inputs so the conclusion holds.

What language must a Field Safety Notice be in?

MDR Article 89 requires the Field Safety Notice to be in the official Union language or languages determined by the member state where the Field Safety Corrective Action is taken, and the content must stay consistent across all member states. That consistency requirement is why terminology control and certified review matter. AD VERBUM keeps one term base across every language version.

Why does the SSCP need two translated versions?

MDR Article 32 requires a Summary of Safety and Clinical Performance in a professional version and a patient version, and the patient version must use plain, non-technical language. Both are made available in the member-state languages through EUDAMED. AD VERBUM writes the patient SSCP for a lay reader while keeping every claim faithful to the professional version.

How fast do serious incident reports have to be translated?

MDR Article 87 sets reporting deadlines as short as 2 days for a serious public-health threat, 10 days for a death or serious deterioration, and 15 days for other serious incidents, and a competent authority can require its national language. Agreeing device terminology in every required language in advance is what makes a fast translation possible. AD VERBUM prepares that vocabulary before an incident occurs.

Can machine translation be used for post-market safety documents?

Only with certified human post-editing under ISO 18587, and not for the parts a patient reads. Raw segment-level machine translation loses cross-document consistency and can soften a warning, which is a compliance defect under MDR Article 89. AD VERBUM uses a client-tuned LLM constrained by your term base, followed by certified device-linguist review.